---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-23-000833"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:17:37.178115+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Lexaria engages InClin as CRO for Phase 1b hypertension study; budget $1.4M

## Summary
- Master Services Agreement with InClin for FDA-registered Phase 1b hypertension study HYPER-H23-1 using DehydraTECH-powered cannabidiol.
- Initial work order budget $1,395,000; includes $72,355 (10% direct costs) and $335,242 (50% pass-through costs).
- Financing of at least US$1,000,000 completed, making the work order definitive.
- Both MSA and work order can be terminated with or without cause on 30 days' notice.
- Kick-off meeting between Lexaria and InClin scheduled for late May 2023.

## SEC filing metadata
- accession: 0001640334-23-000833
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.0
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000833/0001640334-23-000833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000833/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-23-000833
- JSON: https://secwatch.observer/filing/0001640334-23-000833.json
- Plain text: https://secwatch.observer/filing/0001640334-23-000833.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.